The Symplicity HTN-3 study is a, multi-center, prospective, single-blind, randomized, controlled study of the safety and effectiveness of renal denervation in subjects with uncontrolled hypertension. Bilateral renal denervation will be performed using the Symplicity Catheter - a percutaneous system that delivers radiofrequency (RF)energy through the luminal surface of the renal artery.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- device : Renal denervation (Symplicity Catheter System)
- drug : Maintained base-line anti-hypertensive medications
- other : Renal angiogram
Phase: Phase 3
Ages Eligible For Study:
- Individual is ? 18 and ? 80 years old at time of randomization. - Individual is receiving a stable medication regimen including full tolerated doses of 3 or more anti-hypertensive medications of different classes, of which one must be a diuretic (with no changes for a minimum of 2 weeks prior to screening) that is expected to be maintained without changes for at least 6 months. - Individual has an office systolic blood pressure (SBP) of ? 160 mmHg based on an average of 3 blood pressure readings measured at both an initial screening visit and a confirmatory screening visit